Ipsen Regulated Information | Investor Relations
Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. Investors
  3. Regulated Information

Regulated Information

  • Regulated Information
  • Shareholders Meeting

Period

recent search

Reset

Showing: 1 – 05 of 166 Regulated Information

26 July 2022

26 July 2022

Download Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed

19 July 2022

19 July 2022

Download Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed

06 July 2022

06 July 2022

Download Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

06 July 2022

06 July 2022

Download Ipsen – Half year statement – 2022 06 30
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Ipsen – Half year statement – 2022 06 30

05 July 2022

05 July 2022

Download Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agrege
Share On Social Media
Share on LinkedInLinkedIn Share on FacebookFacebook
Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agrege

1 … 28 29 30 31 32 33 34

IPN price

€165.00

 €1.10 (0.67%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue